Research Paper Volume 16, Issue 6 pp 5618—5633

Figure 3. Validation of the applicability of the risk model in patients with TERTp-mutant gliomas. (A) Patients with TERTp-mutant gliomas in the training cohort were divided into high-risk and low-risk groups based on the median risk score. (B) Survival differences between patients in the high- and low-risk scoring groups in the training cohort. (C–E) Diagnostic value of risk models for 1-year, 3-year, and 5-year survival in the training cohort. (F) Survival time as a function of risk score for patients in the training cohort. Green dots represent live cases, and red dots represent dead cases. (G) Heatmap depicting expression levels of HOXC6, WT1, CD70, and OTP in glioma samples in the high-risk and low-risk score groups in the training cohort. (H) Patients with TERTp-mutant gliomas in the test cohort were divided into high-risk and low-risk groups based on the median risk score. (I) Survival differences between patients in the high- and low-risk score groups in the test cohort. (J–L) Diagnostic value of risk models for 1-year, 3-year, and 5-year survival for patients in the test cohort. (M) Survival time as a function of risk score for patients in the high-risk and low-risk scoring groups in the test cohort. Green dots represent living cases, and red dots represent dead cases. (N) Heatmap depicting expression levels of HOXC6, WT1, CD70, and OTP in glioma patients in the high-risk and low-risk scoring groups of the test cohort.